FiberSense CGM System Secures CE Mark; AMDI™ Fast PCR System Achieves FDA 510(k) Clearance and CLIA Waiver for Near-Patient Respiratory Diagnostics; Icarus Medical Raises $7.2 Million Series A to Drive Next-Phase Growth; Crescom and Mass General Brigham Launch Global Proof of Concept for Pediatric Musculoskeletal AI; VahatiCor Reaches Key Milestone with First U.S. Patient Dosed in SERRA-I CMD Study; Sonex Health Unveils Results From Largest-Ever U.S. Investigation of UltraGuideCTR™

FiberSense Continuous Glucose Monitoring (CGM) System obtains CE mark as commercial launch preparations begin  

On 17 June 2026, FiberSense AG announced that its FiberSense Continuous Glucose Monitoring (CGM) System had received CE marking under Regulation (EU) 2017/745 as a Class IIb medical device. The certification authorized the system for the continuous monitoring of glucose levels and glucose trends in adults with diabetes within the European market.

The FiberSense CGM System had been developed using advanced optical sensing technology to measure glucose concentrations in the interstitial fluid beneath the skin, providing users with ongoing insights into their blood sugar patterns during daily activities. To improve convenience and reduce the frequency of routine replacements, the system’s optical sensor and overtape had been designed for wear of up to 28 days before replacement was required, while the detector and charger were intended for repeated use.

Following the achievement of CE marking, FiberSense began transitioning from regulatory approval to commercial preparation. The company initiated activities related to manufacturing scale-up, logistics planning, customer support infrastructure, and market access in selected launch regions. Initial customer orders had already been secured, and the first product deliveries were anticipated for late 2026.

The CGM System represented the first regulated application of FiberSense’s planned continuous multi-analyte (CxM) platform. Although the approved indication focused on continuous glucose monitoring for adults with diabetes, the company continued to advance the development of its broader CxM pipeline, evaluating additional sensing capabilities for biomarkers such as ketones, lactate, and cortisol.

“This certification is a defining milestone for FiberSense,” said Michael Tillmann, Chairman & CEO of FiberSense AG. “After years of dedicated development, our focus now turns to manufacturing scale-up and commercialization.”

As per DelveInsight’s “Blood Glucose Monitoring Systems Market Report,” the blood glucose monitoring systems market was valued at USD 12.12 billion in 2024 and expected to reach USD 18.89 billion by 2032. The Blood Glucose Monitoring Systems Market is expected to grow at a CAGR of 7.72% during the forecast period from 2025 to 2032. The blood glucose monitoring systems market is expanding rapidly due to the rising prevalence of lifestyle style disorders such as diabetes and impaired glucose tolerance, growing product launches and approvals by key players, and a rising preference for minimally invasive techniques that are expected to significantly drive the demand for blood glucose monitoring systems from 2025 to 2032.

AMDI™ Fast PCR System Received FDA 510(k) Clearance and CLIA Waiver for Sub-10-Minute Respiratory Panel 

On 16 June 2026, Autonomous Medical Devices Incorporated (AMDI) announced that the U.S. Food and Drug Administration had granted both 510(k) clearance and CLIA waiver for its AMDI Fast PCR Instrument and Mini Respiratory Panel. The authorization enabled the use of the multiplex RT-PCR assay for the simultaneous detection and differentiation of Respiratory Syncytial Virus (RSV), Influenza A, Influenza B, and SARS-CoV-2 using anterior nasal swab specimens.

The AMDI Fast PCR System had been designed to provide sample-to-answer RT-PCR results in less than 10 minutes, allowing healthcare professionals to obtain actionable diagnostic information during patient visits in urgent care clinics and physician office settings. By delivering results within the “Time of Care™,” the system aimed to facilitate timely clinical decision-making and improve patient management.

The AMDI Mini Respiratory Panel functioned as a four-target molecular assay capable of identifying several major upper respiratory pathogens, including RSV. Rapid detection of RSV remained particularly important because the virus can lead to severe illness among infants, older adults, and individuals with underlying health conditions. The ability to detect and distinguish RSV alongside influenza viruses and SARS-CoV-2 at the point of care supported more informed treatment decisions and infection management during the same clinical encounter.

The FDA clearance and CLIA waiver represented an important milestone for AMDI, strengthening the adoption of rapid molecular testing technologies in decentralized healthcare environments and expanding access to high-performance respiratory diagnostics outside traditional laboratory settings.

“This milestone reflects the coordinated work of teams across AMDI,” said Aiying Sun, EVP, Quality, Regulatory and Clinical Affairs at AMDI. “Pursuing the FDA’s dual 510(k) clearance and CLIA waiver pathway was a deliberate strategy to bring this innovation to market with the validation needed for clinical use in the urgent care setting. It shows that Fast PCR combines strong RT-PCR performance with the simplicity needed for confident molecular testing at the point of care.”

As per DelveInsight’s “Polymerase Chain Reaction Market Report,” the global polymerase chain reaction market was valued at USD 4.90 billion in 2023, growing at a CAGR of 8.66% during the forecast period from 2024 to 2030 to reach USD 8.04 billion by 2030. The PCR market is slated to witness increasing revenue owing to factors such as a rise in the prevalence of diseases caused by pathogens, increasing applications in the field of clinical diagnostics, along with the latest technological advancements to further enhance its accuracy, which is expected to result in the Polymerase Chain Reaction market growth during the forecast period from 2024 to 2030.

Icarus Medical Secured $7.2 Million Series A to Accelerate Growth and Innovation 

On 17 June 2026, Icarus Medical, a Charlottesville-based medical technology company specializing in orthopedic bracing innovations, announced that it had completed its Series A financing round, raising $7.2 million. The round had initially targeted $5 million but closed oversubscribed, demonstrating strong investor confidence in the company’s technology, commercial progress, and long-term growth strategy.

The funds raised were intended to accelerate the commercialization of the company’s products across the United States, advance ongoing product development initiatives, expand manufacturing capabilities, support the clinical validation of its existing devices, and strengthen its workforce as Icarus Medical expanded its national footprint.

Among the key participants in the financing round were Riptide Ventures, OSF Ventures, CU Healthcare Innovation Fund, Highpoint Ventures, MedTech Connect, Neovate Capital Partners, and BLU Venture Investors. Beyond providing financial support, these investors contributed strategic expertise in healthcare, commercialization, operations, and industry networks to assist the company during its next phase of growth.

Icarus Medical’s product portfolio included the Ascender Knee Brace, which had been developed for patients with patellofemoral and multicompartment knee osteoarthritis and featured adjustable unloading and extension-assist technology. The company also offered the Adonis Joint Distraction Knee Brace, designed for individuals with unicompartmental knee osteoarthritis, utilizing dynamic joint distraction technology to reduce pressure within the knee joint.

“This financing represents a major milestone for Icarus Medical and validates both the clinical impact of our technology and the strength of the team we have built,” said Dave Johnson, Founder and CEO of Icarus Medical. “We are excited to partner with investors who not only believe in our mission but who also bring strategic insight and relationships that can help accelerate our trajectory.”

As per DelveInsight’s “Orthopedic Braces and Support System Market Report,” the orthopedic braces and support systems market was valued at USD 4.63 billion in 2023, growing at a CAGR of 5.77% during the forecast period from 2024 to 2030 to reach USD 6.45 billion by 2030. The orthopedic braces and support systems market is growing significantly due to the rising number of trauma and accident cases that cause spinal injuries, the increase in prevalence of degenerative bone disorders such as osteoarthritis and rheumatoid arthritis, rising instances of sports-related injuries, and the increasing prevalence of neuromuscular disorders that are acting as major factors in escalating the demand for orthopedic braces and support systems during the forecast period from 2024 to 2030.

Crescom Launches Global PoC of Pediatric Musculoskeletal AI with Mass General Brigham 

On 16 June 2026, Crescom, a medical artificial intelligence company specializing in musculoskeletal analysis, announced the launch of a global clinical proof-of-concept (PoC) study for its pediatric musculoskeletal AI solutions in collaboration with the Department of Radiology at Mass General Brigham (MGB), one of the largest academic healthcare systems in the United States. The clinical validation initiative was set to be conducted directly by the Department of Radiology at Massachusetts General Hospital (MGH), highlighting the significance of having Crescom’s technology evaluated at one of the world’s leading medical imaging institutions.

The study focused on three of Crescom’s core AI solutions: MediAI-BA, an FDA 510(k)-cleared bone age assessment platform; MediAI-SG, an AI solution for full lower-limb length measurement; and MediAI-SC, an automated scoliosis severity measurement tool. Radiologists at Mass General Brigham compared AI-generated analyses with expert clinical interpretations to evaluate the technologies’ diagnostic accuracy, clinical validity, and real-world usability. Feedback gathered from the U.S. clinical setting was intended to further refine the solutions and support future commercialization efforts in the local market.

The collaboration was initiated against the backdrop of increasing imaging volumes, growing physician burnout, and a shortage of specialized radiologists across the healthcare industry, particularly in the United States. With pediatric imaging specialists in limited supply and demand for imaging services continuing to rise, healthcare providers have shown increasing interest in AI-driven tools capable of streamlining workflows and enhancing efficiency. Through the validation study, Crescom sought to demonstrate, using evidence generated at a globally recognized institution, that its musculoskeletal AI technologies could meaningfully improve the productivity and efficiency of medical specialists.

The partnership with Mass General Brigham was expected to become an important milestone in establishing Crescom’s clinical presence in North America. The company aimed to strengthen its credibility within radiology and pediatric growth clinics, expand relationships with key healthcare institutions in the region, and explore new opportunities by integrating its pediatric musculoskeletal assessment and growth prediction technologies into the North American youth athletic development sector, where significant future demand was anticipated.

According to DelveInsight’s “Artificial Intelligence in Medical Imaging Market Report”, the global artificial intelligence in medical imaging market is expected to increase from USD 1,673.03 million in 2024 to USD 13,181.93 million by 2032, growing at a CAGR of 29.48% during the forecast period from 2025 to 2032.

The global artificial intelligence in medical imaging market is being driven by the rising prevalence of chronic diseases such as cancer, cardiovascular disorders, and neurological conditions, which increase demand for accurate and efficient diagnostics. Government initiatives and funding are promoting healthcare digitization and AI adoption, while key players are investing in product development and strategic collaborations to enhance imaging solutions. Rapid advancements in deep learning, machine learning, and computer vision are further improving diagnostic accuracy, workflow efficiency, and predictive capabilities, collectively accelerating market growth across regions.

VahatiCor Enrolled First U.S. Patient in SERRA-I Clinical Study of A-FLUX Reducer System® for CMD 

On 17 June 2026, VahatiCor, Inc., a medical technology company focused on developing interventional therapies for coronary microvascular dysfunction (CMD), announced that it had enrolled the first patient in the United States in the SERRA-I early feasibility study evaluating its A-FLUX Reducer System®. This achievement expanded upon the initial human experience generated through the SERRA-I program and complemented the ongoing patient enrollment taking place in the European arm of the study.

The SERRA-I trial was designed to assess the initial use of the A-FLUX Reducer System® in patients suffering from symptomatic CMD. Conducted as part of the broader SERRA clinical program, the study involved multiple investigative centers across the United States and Europe. The first U.S. patient was enrolled at Yale-New Haven Hospital, where Samit Shah, MD, PhD, an interventional cardiologist at Yale New Haven Hospital Heart & Vascular Center and Assistant Professor of Medicine at Yale School of Medicine, served as a co-principal investigator for the trial.

The A-FLUX Reducer System® was developed as a self-expanding nitinol implant delivered through a catheter into the coronary sinus. The investigational device was intended to modify coronary blood flow within the heart’s microvasculature and address the underlying dysfunction associated with CMD. Coronary microvascular dysfunction affects millions of individuals who continue to experience persistent angina and related symptoms despite the absence of significant blockages in the major coronary arteries. The device remained investigational and had not received approval from the U.S. Food and Drug Administration for commercial use.

“Treating our first U.S. patient brings the A-FLUX Reducer System into U.S. clinical investigation,” said Harry D. Rowland, PhD, Chief Executive Officer of VahatiCor. “Cardiology is moving toward treating microvascular disease as a frontline condition, and the A-FLUX Reducer System is built for this shift. I’m grateful to the SERRA-I investigators and to the patients who are making this study possible.”

According to DelveInsight’s ”Interventional Cardiology Devices Market Report,” the global interventional cardiology devices market is expected to increase from USD 20,192.60 million in 2024 to USD 34,866.30 million by 2032, growing at a CAGR of 7.09% during the forecast period from 2025 to 2032. The global interventional cardiology devices market is driven by the growing prevalence of cardiovascular diseases (CVDs) and their associated risk factors, increasing preference for minimally invasive procedures, increasing technological advancement in product design, and an increase in strategic activities among the key market players.

Sonex Health Announced Data From Largest-Ever U.S. Study Proving Ultraguidectr™ Delivers Compelling Results for Carpal Tunnel Patients 

On 10 June 2026, Sonex Health, Inc. and The Institute of Advanced Ultrasound Guided Procedures announced the publication of six-month clinical data demonstrating the safety and effectiveness of ultrasound-guided carpal tunnel release (UGCTR) performed using the UltraGuideCTR™ system. The results, published in the Journal of Hand Surgery Global Online, represented the largest prospective evaluation of the procedure conducted to date.

The findings were generated from the MISSION registry (Post-Market Registry of the Patient Experience when using UltraGuideCTR for Carpal Tunnel Release), a prospective, multicenter study designed to collect real-world clinical outcomes from patients undergoing treatment for carpal tunnel syndrome (CTS) in routine U.S. clinical practice. The registry evaluated outcomes among patients treated with UltraGuideCTR™, endoscopic carpal tunnel release (ECTR), and open carpal tunnel release (OCTR), to compare symptom improvement, functional recovery, pain reduction, quality of life, and patient satisfaction across the different treatment approaches.

The six-month analysis included data from 887 patients and 1,082 treated hands across 22 clinical sites in the United States. The study found that patients who underwent ultrasound-guided carpal tunnel release experienced rapid and sustained improvements in symptoms, hand function, and pain levels compared with baseline measurements. Most patients resumed normal daily activities within a median of three days and returned to work within four days following the procedure.

Patient satisfaction remained high throughout the six-month follow-up period, with nearly 90% of treated hands reporting positive outcomes. The majority of procedures were performed using wide-awake local anesthesia without a tourniquet (WALANT), eliminating the need for general anesthesia in many cases. The procedures were completed through a small wrist incision averaging approximately 5 mm, and most cases did not require sutures for wound closure.

The study also demonstrated the feasibility of treating both hands during a single procedure for patients with bilateral carpal tunnel syndrome, with clinical outcomes comparable to those observed in patients treated on only one hand. Importantly, investigators reported no intraoperative complications or serious adverse events, further supporting the safety and effectiveness of the ultrasound-guided minimally invasive approach for carpal tunnel syndrome treatment.

“This paper is significant because the results demonstrate real-world, patient-reported experiences across the largest set of CTS patients in a single study, establishing a new benchmark for safety, efficacy, and patient outcomes in carpal tunnel release procedures,” said Dr. Victor Marwin, an orthopedic hand surgeon with Bluegrass Orthopaedics in Lexington, Ky., and principal investigator for MISSION.

According to DelveInsight’s “Minimally Invasive Surgical Devices Market Report,” the global minimally invasive surgical devices market is expected to increase from USD 30,798.01 million in 2025 to USD 53,259.85 million by 2034, growing at a CAGR of 7.13% during the forecast period from 2026 to 2034. The market of minimally invasive surgical devices is being primarily driven by the rising prevalence of chronic diseases such as cancer, cardiovascular disorders, increasing technological advancement in surgical devices, and an increase in product development activities among the key market players globally.